SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 733.
  • 2
    Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 52530.
  • 3
    Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Toxicol 1998; 38: 97120.
  • 4
    Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90: 160920.
  • 5
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 340610.
  • 6
    Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645.
  • 7
    Gelman L, Fruchart J-C, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999; 55: 83243.
  • 8
    Zhu Y, Qi C, Korenberg JR. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci USA 1995; 92: 79215.
  • 9
    Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor-γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 76149.
  • 10
    Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou J-P, Staels B, Auwrex J, Laville M, Vidal H. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 48: 131927.
  • 11
    Clay CE, Namen AM, Fonteh AN, Atsumi G, High KP, Chilton FH. 15-deoxy-Δ12,14PGJ2 induces diverse biological responses via PPARγ activation in cancer cells. Prostaglandins Other Lipid Mediat 2000; 62: 2332.
  • 12
    Callejas NA, Castrillo A, Bosca L, Martin-Sanz P. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators. J Pharmacol Exp Ther 1999; 288: 123541.
  • 13
    Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999; 20: 190511.
  • 14
    Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson HI. Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 1997; 10: 5037.
  • 15
    Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90: 45560.
  • 16
    Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 6325.
  • 17
    Jiang WG, Redferm A, Bryce RP, Mansel RE. Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of γ-linolenic acid in breast cancer cells. Prostaglandin Leukot Essent Fatty Acids 2000; 62: 11927.
  • 18
    Harris ER, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 21013.
  • 19
    Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett 2002; 184: 712.
  • 20
    Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ) GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 56713.
  • 21
    Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8: 97114.
  • 22
    Elsner E, Muller C, Koshizuka K, Williamson EA, Park D, Aso H, Shintaku P, Said JW, Heber D, Koeffler P. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 880611.
  • 23
    Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 2002; 20: 6516.
  • 24
    Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N, Hattori K, Reddy JK, Oyasu R. Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159: 5917.
  • 25
    DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochem Biophys Acta 1991; 1083: 12134.
  • 26
    Bishop HM, Haynes A, Evans DF, Elston CW, Johnson J, Blamey RW. Radioimmunoassay of prostaglandin E2 in primary breast cancer and its relationship to histological grade. Clin Oncol 1980; 6: 3801.
  • 27
    Gunasegaram R, Loganath A, Peh KL, Chiang SC, Ratnam SS. Identification of prostaglandins in infiltrating duct carcinoma of the human breast. IRCS Med Sci 1981; 8: 7478.
  • 28
    Karmali RA, Walt S, Thaler HT, Lefever F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 1983; 48: 68996.
  • 29
    Fulton AM, Ownby HE, Frederick J, Brennan MJ. Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: clinical update. Invasion Metastasis 1986; 6: 8394.
  • 30
    Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 185639.
  • 31
    Stephen M, Perscott FA, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochem Biophys Acta 2000; 1470: M6978.
  • 32
    Badawi AF. The role of prostaglandin synthesis in prostate cancer. Br J Urol Int 2000; 85: 45162.
  • 33
    Kundu N, Yang Q, Dorsey R, Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 2001; 93: 6816.
  • 34
    Liu X-H, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56: 51257.
  • 35
    Bennett A, Berstock DA, Raja B, Stamford IF. Survival time after surgery is inversely related to the amount of prostaglandins extracted from human breast cancer. Br J Pharmacol 1979; 66: 451.
  • 36
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980; 64: 106170.
  • 37
    McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1986; 45: 18038.
  • 38
    McCormick DL, Moon RC. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br J Cancer 1983; 48: 85961.
  • 39
    Gimble JM, Pighetti GM, Lerner MR, Wu X, Lightfoot SA, Brackett DJ, Darcy K, Hollingsworth AB. Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochem Biophys Res Commun 1998; 253: 8137.
  • 40
    Fukushim M, Kato T, Narumiya S, Mizushima Y, Sasaki H, Terashima Y, Nishiyama Y, Santoro MG. Prostaglandin A and J: anti-tumor and antiviral prostaglandins. Adv Prostaglandin Thromboxane Leukot Res 1989; 19: 4158.
  • 41
    Simmons D, Xie W, Chipman JG, Evett GE. Multiple cyclooxygenases: cloning of a mitogen-inducible form. In: BaileyJM, ed. Prostaglandin, leukotrienes, lipoxins and PAF. New York: Plenum Press, 1991. 6778.
  • 42
    Hedqvist P, Raud J, Dahlen SE. Dual action of prostaglandin E2 in allergic inflammation. Adv Prostaglandin Thromboxane Leukot Res 1989; 19: 53942.
  • 43
    Colville-Nash PR, Qureshi SS, Willis D, Willoughby DA. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol 1998; 161: 97884.
  • 44
    Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein-p300. J Biol Chem 2001; 276: 124408.
  • 45
    Saso L, Leone MG, Sorrentino C, Giacomelli S, Silverstrini B, Grima J, Li JC, Samy E, Mruk D, Cheng CY. Quantification of prostaglandin D synthase in cerebrospinal fluid: a potential marker for brain tumor. Biochem Mol Biol Int 1998; 46: 64356.
  • 46
    Hirata Y, Hayashi H, Ito S, Kikawa Y, Ishibashi M, Sudo M, Miyazaki H, Fukushima M, Narumiya S, Hayaishi O. Occurrence of 9-deoxy-d9Δ12-13l4-dihydroprostaglandin D2 in human urine. J Biol Chem 1988; 263: 1661925.
  • 47
    Katayama S, Maruno Y, Itabashi A, Inaba M, Akabane S, Tanaka K, Tanaka K, Shibuya M, Kawazu S, Ishii J. Effect of dietary calcium on renal prostaglandins. Prostaglandin Leukot Essent Fatty Acids 1991; 42: 197200.
  • 48
    Xing G, Zhang L, Heynen T, Yoshikawa T, Smith M, Weiss S, Detera-Wadleigh S. Rat PPAR-δ contains a CGG triplet repeat and prominently expressed in the thalamic nuclei. Biochem Biophys Res Commun 1995; 217: 101525.
  • 49
    Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochem Biophys Acta 1996; 1302: 93109.
  • 50
    Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997; 73: 37180.
  • 51
    Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 44249.
  • 52
    Badawi AF, Archer MC. Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Prostaglandins Other Lipid Mediat 1998; 56: 16781.
  • 53
    Schrey MP, Patel KV. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 1995; 72: 14129.
  • 54
    Patel KV, Sheth HG, Schrey MP. Stimulation or endothelin-1 secretion by human breast cancer cells through protein kinase A activation: a possible novel paracrine loop involving breast fibroblast-derived prostaglandin E2. Mol Cell Endocrinol 1997; 126: 14351.
  • 55
    Yang W-L, Frucht H. Activation of PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001; 22: 137983.
  • 56
    Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998; 1: 46570.
  • 57
    Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 205772.
  • 58
    Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ. Int J Oncol 2002; 20: 110922.